BEIJING, Sept. 29, 2026 /PRNewswire/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced that it will report its financial results for the first quarter ended August 31, 2026, before the U.S. market opens on October 28, 2026. New Oriental's management will host an earnings conference call at 8 AM on October 28, 2026, U.S. Eastern Time (8 PM on October 28, 2026, Beijing/Hong Kong Time). Participants can join the conference using the below options:

Dialling-in to the conference call:

Please register in advance of the conference, using the link provided below. Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.

Conference call registration link:

https://register-conf.media-server.com/register/BId978053d1f894490876e8d3906094a10. It will automatically direct you to the registration page of "New Oriental FY2027 Q1 Earnings Conference Call" where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial in number(s) and personal PIN) provided in the confirmation email received at the point of registering.

Joining the conference call via a live webcast:

Additionally, a live and archived webcast of the conference call will be available at http://investor.neworiental.org.

Listening to the conference call replay:

A replay of the conference call may be accessed via the webcast on-demand by registering at https://edge.media-server.com/mmc/p/d5kv97n5 first. The replay will be available until October 28, 2027.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

Contacts

SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") signed a US$300 million portfolio credit insurance policy and an initial US$50 million non-recourse factoring agreement at the Zoomlion 2026 Global Financial Partners Summit and Signing Ceremony in Shanghai on September 11, establishing a tiered insurance-and-financing framework for overseas installment receivables as its international business grows.

Developed over six months with international insurers and financial institutions, the arrangement combines portfolio credit insurance with non-recourse factoring. In practical terms, overseas installment receivables covered by the insurance policy can be factored with an overseas bank on a non-recourse basis. This gives Zoomlion a structured way to manage and finance overseas receivables rather than handling them transaction by transaction. The framework is designed to turn these receivables into scalable, standardized and replicable investment-grade assets.

At the signing ceremony, the US$300 million policy was signed with a double-A-rated international insurer and leading institutions, while the initial US$50 million non-recourse factoring agreement was signed with an overseas bank.

The agreements come as Zoomlion continues to expand internationally. In the first half of 2026, the company's international revenue rose 12.45% year over year to RMB 15.54 billion (approximately US$2.31 billion), accounting for 57.25% of total revenue.

Zoomlion CFO Du Yigang reviewed the company's cooperation with global financial partners and outlined its progress and future plans for overseas financial and insurance services.

"Zoomlion will continue to uphold the values of Integrity, Dedication, Inclusiveness and Responsibility and deepen mutual trust with our financial partners," said Du.

More than 40 financial and insurance partners from Singapore, Indonesia, Thailand, France, Kazakhstan, Hong Kong SAR and other markets attended the summit. Discussions covered the global macroeconomic outlook, overseas financial and insurance strategies, regional market opportunities, exchange and interest rate trends, and insurance innovation. The Economist Corporate Network (ECN) led a morning session on macroeconomic and geopolitical trends, while representatives from Radana and Alfa-Bank shared perspectives on market and financing developments.

Xu Xiaoming, General Manager of Zoomlion's Financial Business Management Department and Credit Insurance Department, discussed future cooperation, while Deputy General Manager Yan Xin introduced the company's overseas third-party financing and insurance strategy and cooperation models.

Looking ahead, Zoomlion plans to deepen cooperation with global financial and insurance partners and further develop scalable and replicable financial and insurance solutions to support its international growth.

• HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing          
• Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) today announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding the Chinese mainland, the Hong Kong SAR, the Macao SAR and Taiwan Region. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

"We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration," said Frank Jiang, MD, PhD, Executive Vice President and Chief Strategy Officer of Hengrui Pharma. "This collaboration brings together Hengrui's innovation strengths and Novo's global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide."

"Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation," said Martin Holst Lange, MD, PhD, Executive Vice President, Research & Development and Chief Scientific Officer at Novo. "Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field."

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase I clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Novo

Novo is the global healthcare company that believes lasting health starts now. For over a century, we've combined leading scientific expertise with a deep understanding of people's lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we're working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

About Hengrui Pharma

Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

Hengrui Pharma Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that reflect Hengrui Pharma's beliefs or expectations about the future or future events as of the respective dates indicated therein ("forward-looking statements"). These forward-looking statements are based on a number of assumptions about Hengrui Pharma's operations, its future development plans, market (financial and otherwise) conditions and growth prospects, and are subject to significant risks, uncertainties and other factors beyond Hengrui Pharma's control, and accordingly, actual results may differ materially from those contemplated by these forward-looking statements. No reliance should be placed on such statements, which reflect the view of the management of Hengrui Pharma as at the date of this press release. Hengrui Pharma does not undertake any obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates.

Meta Platforms, Inc. (META.US) announced the launch of the enterprise platform Meta Enterprise Platform, which CEO Mark Zuckerberg described as Meta's next major pillar. In a research report, Citi said Meta Enterprise will commercialize products including the company's Muse agent, Meta Business Agent, Muse API and Muse Code, and has hired MongoDB CEO CJ Desai for the initiative.

Citi noted that Muse is scaling up and its model API is now generally available. Together with the company's development of the next-generation flagship LLM Watermelon, Citi believed the launch of Meta Enterprise Platform reflects that the company will still have sufficient computing power capacity through 2027.

The broker forecast Meta's computing power capacity will expand drastically to around 14GW by 2027. Although capacity constraints remain at present, Prometheus, third-party partnerships and broader infrastructure investments should unlock incremental capacity to support both internal product development and external monetization plans.

Citi reiterated its Buy rating on Meta with a TP of USD800.
~

AASTOCKS Financial News
Website: www.aastocks.com

NVIDIA Corporation (NVDA.US) shares rose on Monday (28th) after the chip giant announced the largest share buyback plan in its history.

The company said it increased its share repurchase authorization by USD150 billion. As NVIDIA Corporation (NVDA.US) still has a substantial remaining balance under its previous authorization, management can now deploy USD235 billion through the repurchase program.

NVIDIA plans to execute the remaining repurchase quota by the end of FY2028, which ends in January 2028.

NVIDIA CEO Jensen Huang said in a statement that their cash generation capability enables them to invest in the technologies driving this transformation while returning capital to shareholders. This authorization reflects their confidence in the long-term opportunities ahead.
~

AASTOCKS Financial News
Website: www.aastocks.com

Anthropic logged a USD42 billion loss last year, while revenue swelled 11x to nearly USD4.6 billion, Reuters, citing Anthropic's prospectus filing, reported. Operating loss crossed USD8 billion, but the company still plans to invest USD518 billion in cloud, computing and infrastructure commitments.

Anthropic pumped USD7.33 billion in computing and infrastructure last year, tripling from 2024 and accounting for more than half of its total operating expenses of USD12.65 billion. The nearly USD42 billion loss last year included an accounting charge of about USD34 billion, reflecting increases in the valuation of financings that could eventually convert into Anthropic shares, rather than cash spent on operating activities.
~

AASTOCKS Financial News
Website: www.aastocks.com

Advanced Micro Devices, Inc. (AMD.US) agreed to acquire World Labs for USD8.2 billion. The all-stock transaction is anticipated to be completed before the end of 2026, subject to regulatory approvals.

World Labs was founded by AI pioneer Fei-Fei Li, who will join AMD as Executive Vice President and Chief Scientist, reporting directly to AMD CEO Lisa Su.

Su said the acquisition will not only bring world-class talent such as Li to the company, but also combine World Labs' capabilities with AMD's strengths in hardware, software and systems.
~

AASTOCKS Financial News
Website: www.aastocks.com

This morning (28th), the HSI opened up 44 pts and once sharpened its gains to more than 250 pts before closing at 24,642, up 132 pts or 0.54%. Main board turnover for the day reached HKD177.482 billion. The HSCEI closed at 8,216, up 51 pts or 0.63%, while the HSTECH dipped 15 pts or 0.37% to close at 4,296.

Major techs traded mixed. NTES (09999.HK) outshone, closing up 4.86% as the best-performing blue chip. TENCENT (00700.HK) inched up 0.73%, while BABA-W (09988.HK) sank 0.65% and XIAOMI-W (01810.HK) faded 0.15%.

Optical communication concept stocks came under pressure after a US senator proposed legislation related to optical modules, listing ZJ INNOLIGHT (03308.HK) and Eoptolink as restricted suppliers. ZJ INNOLIGHT closed at the day's trough, plunging 12.21% to HKD1,028. YOFC (06869.HK) tumbled 16.62%, while CIG (06166.HK) nosedived 11.93%.

Following price cuts by several large-model developers in September, Hong Kong-listed large-model stocks subtracted. MINIMAX-W (00100.HK) cascaded 9.08%, Z.AI (02513.HK) cratered 1.82%, and XUNCE (03317.HK) tumbled 7.18%.

Chip stocks were pressured by reports that China may allow companies such as Alibaba to purchase high-end chips from NVIDIA Corporation (NVDA.US). HUA HONG GRACE (01347.HK) fell off 4.62%, making it the worst-performing blue chip. SMIC (00981.HK) crashed 3.63%, MONTAGE TECH (06809.HK) stumbled 5.12%, ILUVATAR COREX (09903.HK) slumped 11.37%, and GIGADEVICE (03986.HK) plunged 7.2%.

After US President Donald Trump turned down Iran's ceasefire proposal, oil prices advanced, shoring up China's three oils. PETROCHINA (00857.HK) shot up 3.08%, CNOOC (00883.HK) hiked 1.2%, and SINOPEC CORP (00386.HK) added 1.69%.

Concerns that elevated oil prices may force the Fed to further raise interest rates pushed spot gold down more than 3%. SD GOLD (01787.HK) plummeted 9.35%, LINGBAO GOLD (03330.HK) slumped 10%, ZIJIN MINING (02899.HK) skydived 2.65%, ZIJIN GOLD INTL (02259.HK) cratered 2.94%, and ZHAOJIN MINING (01818.HK) slid 5.83%.
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Electronics Chairman Lee Jae-yong, SK Group Chairman Chey Tae-won and NVIDIA Corporation (NVDA.US) CEO Jensen Huang will meet at the Korea Society annual gala dinner to be held in New York on Monday (28th). This marks another gathering of top executives from the three chip giants after their meeting in San Francisco about two months ago.

The market sheds light on cooperation among the three companies in HBM supply and expansion of AI infrastructure collaboration. Samsung is accelerating supplies of HBM4 for NVIDIA's next-generation Vera Rubin accelerators, while SK Group is seeking comprehensive partnership cooperation in areas including AI factory construction.
~

AASTOCKS Financial News
Website: www.aastocks.com

This morning (28th), the HSI opened up 44 pts and once soared more than 200 pts. It closed midday at 24,666, up 156 pts or 0.64%, with half-day turnover reaching HKD94.785 billion. The HSCEI closed midday at 8,212, up 46 pts or 0.57%. The HSTECH closed midday at 4,288, down 23 pts or 0.54%.

Major tech stocks were in a mixed bag. NTES (09999.HK) mounted 4.42%, making it the best-performing blue chip. TENCENT (00700.HK) gained 0.87%. BABA-W (09988.HK) lost 1.48%, while XIAOMI-W (01810.HK) sank 0.77%.

Optical communications concept stocks came under pressure after a US senator proposed legislation related to optical modules, listing ZJ INNOLIGHT (03308.HK) and Eoptolink as restricted suppliers. ZJ INNOLIGHT tumbled 9.39%, YOFC (06869.HK) slumped 13.83%, and CIG (06166.HK) plunged 9.33%.

Several large AI models cut prices in September, weighing down Hong Kong-listed large model stocks. MINIMAX-W (00100.HK) plummeted 8.87%, Z.AI (02513.HK) declined 2.05%, and XUNCE (03317.HK) eroded 5.29%. Printed circuit board (PCB)-related stocks were broadly sold off. KB LAMINATES (01888.HK) and KINGBOARD HLDG (00148.HK) each crashed more than 7%, VGT (02476.HK) stumbled 9.49%, and HANS CNC (03200.HK) slid 7%.

Chip stocks were subdued as China may reportedly allow companies such as BABA-W (09988.HK) to purchase high-end chips from NVIDIA Corporation (NVDA.US). HUA HONG GRACE (01347.HK) fell off 4.8%, making it the worst-performing blue chip. SMIC (00981.HK) cratered 3.55%, MONTAGE TECH (06809.HK) lost 4.72%, ILUVATAR COREX (09903.HK) collapsed 8.04%, and GIGADEVICE (03986.HK) shrank 5.67%.
~

AASTOCKS Financial News
Website: www.aastocks.com